PIL on Tuesday 16th May
|When:||Tu 16-05-2017 12:00 - 13:00|
Mitochondrial diseases are a group of clinically, biochemically and genetically heterogeneous disorders affecting cellular energy metabolism and leading to multi-systemic progressive, often early fatal, disorders, with an unmet medical need. In this lecture I will present the current landscape of drug development for mitochondrial disease and then discuss in more detail the path of our own lead molecule KH176 currently evaluated in a Phase 2 clinical trial.
Mitochondrial disease: small molecule drug development